PRECLINICAL STUDIES TO ASSESS ACUTE AND CHRONIC TOXICITIES OF A CANDIDATE DRUG BASED ON COMPLEMENT C3 NEODETERMINANT RECOMBINANT HUMANIZED ANTIBODY FOR TREATMENT OF TRAUMATIC BRAIN INJURIES
http://eng.biomos.ru/conference/articles.htmBIOTECHNOLOGY: STATE OF THE ART AND PERSPECTIVES(2021)
摘要
A drug based on complement C3 neodeterminant recombinant humanized antibody for the treatment of traumatic brain injuries belongs to the class III of low-risk drugs.
更多查看译文
关键词
recombinant humanized antibody
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要